Wegovy HD Approved: 20.7% Weight Loss With New 7.2mg Dose

The FDA just approved semaglutide 7.2mg — the highest dose ever — delivering 20.7% average weight loss. Here's what men need to know about Wegovy HD.

What Is Wegovy HD?

Wegovy HD is a higher-dose formulation of semaglutide — the same active ingredient in Wegovy (2.4mg) and Ozempic. The "HD" stands for high dose, coming in at 7.2mg per weekly injection, exactly three times the current standard Wegovy dose.

The FDA approved it under the Competitive New Product Voucher pilot program, which fast-tracks drugs addressing national health priorities. From filing to approval took just 54 days — signaling how seriously regulators view the obesity crisis.

The STEP UP Trial Results

The approval is backed by the STEP UP phase 3 clinical trial, which enrolled adults with obesity or overweight with at least one weight-related condition. The headline numbers are significant:

Metric	Wegovy HD (7.2mg)	Standard Wegovy (2.4mg)
Mean weight loss	20.7%	~15%
Achieved ≥25% loss	~33% of participants	~12%
Dosing	Once weekly	Once weekly
Trial duration	72 weeks	68 weeks

For a 220-pound man, 20.7% weight loss translates to roughly 45 pounds. And one in three participants hit the 25% threshold — that's potentially 55+ pounds for the same starting weight.

Why This Matters for Men

Men metabolize semaglutide differently than women. Higher lean muscle mass means a larger volume of distribution, and some research suggests men may benefit from higher doses to achieve equivalent appetite suppression. Wegovy HD addresses this directly.

The cardiovascular benefit is equally important. The SELECT trial already proved semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% — and heart disease remains the leading killer of American men. Wegovy HD carries the same cardiovascular indication.

Side Effects at Higher Doses

The safety profile is consistent with standard semaglutide, with gastrointestinal side effects remaining the most common:

• Nausea: Most common, especially during dose escalation
• Diarrhea and vomiting: Generally mild to moderate
• Altered skin sensation: A new finding at this dose — sensitivity, pain, or burning that typically resolves with dose reduction

When Will It Be Available?

Novo Nordisk expects to launch Wegovy HD in a single-dose pen format in the US starting in mid-2026. Pricing hasn't been announced yet, but it will likely align with the existing Wegovy pricing structure.

In the meantime, current GLP-1 options remain available through telehealth providers — including both brand-name and compounded formulations at significantly lower price points.

How Wegovy HD Fits the GLP-1 Landscape

This approval comes alongside several other major developments in the GLP-1 space:

• Oral Wegovy (25mg pill) launched January 2026 at $149/month — the first GLP-1 pill for weight loss
• Eli Lilly's orforglipron (oral tirzepatide alternative) is expected to be FDA-reviewed by end of 2026
• FDA 503B Bulks List proposal could restrict compounded GLP-1 access — public comments due June 29, 2026

Men now have more options than ever: standard injectable semaglutide, high-dose semaglutide, oral semaglutide, tirzepatide, or compounded alternatives through telehealth platforms.

Current Provider Options

The Bottom Line

Wegovy HD represents a meaningful step forward in obesity treatment — 20.7% average weight loss with one in three patients hitting 25%. For men who plateau on standard doses or need more aggressive intervention, this higher dose could be a turning point. Talk to a provider about whether the standard or HD formulation makes sense for your situation.